Compare PFGC & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PFGC | MEDP |
|---|---|---|
| Founded | 1885 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9B | 17.2B |
| IPO Year | 2014 | 2016 |
| Metric | PFGC | MEDP |
|---|---|---|
| Price | $108.17 | $652.95 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 14 |
| Target Price | $123.92 | ★ $651.31 |
| AVG Volume (30 Days) | ★ 1.7M | 304.8K |
| Earning Date | 11-04-2026 | 10-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.05 | ★ 20.98 |
| EPS | 0.82 | ★ 13.37 |
| Revenue | ★ $17,619,900,000.00 | N/A |
| Revenue This Year | $13.14 | $12.62 |
| Revenue Next Year | $2.97 | $6.03 |
| P/E Ratio | $133.62 | ★ $49.12 |
| Revenue Growth | ★ 5.12 | N/A |
| 52 Week Low | $80.82 | $373.00 |
| 52 Week High | $117.48 | $693.97 |
| Indicator | PFGC | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 66.47 | 52.91 |
| Support Level | $89.85 | $575.64 |
| Resistance Level | $116.31 | $685.94 |
| Average True Range (ATR) | 2.66 | 25.44 |
| MACD | 1.41 | -2.83 |
| Stochastic Oscillator | 74.95 | 46.98 |
Performance Food Group is one of the largest foodservice distributors in the US, with sales of just under $68 billion in fiscal 2026. It sells and distributes food and nonfood products through its foodservice segment, which serves restaurants and institutions, accounting for 54% of sales. PFG also wholesales and distributes products to convenience stores (38%) and through its specialty segment (8% of sales), which serves customers such as vending operators, office coffee service providers, and theaters. The firm's platform spans 250,000 products offered to 300,000 customer locations, supported by over 150 distribution centers across all three segments.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.